Disseminated on behalf of ARMR Sciences Inc.
Fentanyl is no longer just another opioid – it has become the single most lethal synthetic drug in the United States. Since 2000, it is estimated that more than 20 million nonfatal overdoses have occurred in the U.S.- surpassing deaths from COVID-19, HIV/AIDS, and even major wars.
Today, fentanyl is the leading cause of death for adults aged 18–45, claiming an estimated 220 lives every single day.
A Silent, Rapid Killer
A minuscule amount – equivalent in size to just a few grains of salt – can be fatal. Fentanyl is fast-acting and often hidden in counterfeit pills or laced into drugs without the user’s knowledge.
Fentanyl is cheap to manufacture and covertly laced with counterfeit pills and recreational drugs. This stealth factor explains why the vast majority of overdose victims never intended to take fentanyl.
The financial toll is also staggering: the opioid epidemic costs the U.S. economy an estimated $2.7 trillion in 2023 alone, with cumulative losses exceeding $10 trillion over the past two decades.
Why Current Defenses Fall Short
Tools like naloxone (Narcan) have saved lives but remain purely reactive. They only work after an overdose begins and often fail against emerging analogs such as xylazine, nitazenes, or medetomidine, which Narcan cannot reverse. First responders, military personnel, and even families are left without effective long-term defenses.
ARMR’s Preventive Approach
ARMR Sciences is advancing its novel immunotherapy, ARMR-100, designed to train the immune system to block fentanyl before it reaches the brain. In animal studies, ARMR-100 blocked 92% of fentanyl’s entry into the brain and eliminated its addictive behavioral effects.
Unlike reactive antidotes, this would provide months of protection – functioning like a biochemical shield.
The program is building on seven years of U.S. Department of Defense–funded research and is working to leverage proven vaccine components, such as carrier proteins already approved in licensed products and adjuvants tested in hundreds of clinical trials.
The Market and ARMR’s Mission
The potential reach is vast: 2.7 million Americans with opioid use disorder, over 2 million first responders and law enforcement officers, more than 18 million military personnel and veterans who experience higher rates of opioid use, chronic pain, and post-traumatic stress disorder, and more than 30 million high-risk young people.
A once or twice annual preventive shot could help transform national defense against fentanyl, making protection scalable across households, schools, hospitals, and security agencies.
The fentanyl crisis is no longer just a health issue – it’s a national security emergency. And we believe prevention, not rescue, may be the only path to saving a generation.
Why Investors Should Pay Attention
ARMR is more than a biotech startup – it is working to tackle America’s most urgent social and health crisis. This is a mission-driven company focused on building a preventive defense platform that could save thousands of lives each year:
- $30M private raise launched
- Seven years of DoD-backed research form the foundation
- Lead candidate ARMR-100 blocked 92% of fentanyl from entering the brain in preclinical studies
- A targeted exchange listing in the future
By investing in this round, investors have a chance to back a company whose mission is as much about impact as it is about growth potential.
This is a paid advertisement for ARMR’s private offering. Please read the offering circular at InvestARMR.com for additional information on the company and the risk factors related to the offering.
DISCLOSURES & DISCLAIMERS
CLIENT CONTENT: Carboncredits.com is not responsible for any content hosted on ARMR Sciences’ sites; it is ARMR Sciences’ responsibility to ensure compliance with applicable laws.
NOT INVESTMENT ADVICE: Content is for educational, informational, and advertising purposes only and should NOT be construed as securities-related offers or solicitations. All content should be considered promotional and subject to disclosed conflicts of interest.
Do NOT rely on this as personalized investment advice. Do your own due diligence.
Carboncredits.com strongly recommends you consult a licensed or registered professional before making any investment decision.
REGULATORY STATUS: Neither Carboncredits.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
CONTENT & COMPENSATION DISCLOSURE: Carboncredits.com has received compensation of thirty thousand dollars from ARMR Sciences for this sponsored content. You should assume we receive compensation as indicated for any purchases through links in this email via affiliate relationships, direct/indirect payments from companies or third parties who may own stock in or have other interests in promoted companies. We may purchase, sell, or hold long or short positions without notice in securities mentioned in this communication.
RESULTS NOT TYPICAL: Past performance and results are unverified and NOT indicative of future results. Results presented are NOT guaranteed as TYPICAL. Market conditions and individual circumstances vary significantly. Actual results will vary widely. Investing in securities is speculative and carries high risk; you may lose some, all, or possibly more than your original investment.
HIGH-RISK: Securities discussed may be highly speculative investments subject to extreme volatility, limited liquidity, and potential total loss. The Securities are suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that such investment could be illiquid for an indefinite period of time. No public market currently exists for the securities, and if a public market develops, it may not continue.
Disclosure: Owners, members, directors, and employees of carboncredits.com have/may have stock or option positions in any of the companies mentioned: None.
Carboncredits.com receives compensation for this publication and has a business relationship with any company whose stock(s) is/are mentioned in this article.
Additional disclosure: This communication serves the sole purpose of adding value to the research process and is for information only. Please do your own due diligence. Every investment in securities mentioned in publications of carboncredits.com involves risks that could lead to a total loss of the invested capital.
